 Shares of CytoSorbents NASDAQ:CTSO fell 2.15 in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 27.27 year over year to 0.08, which were in line with the estimate of 0.08.Revenue of 9,795,000 rose by 57.17 from the same period last year, which beat the estimate of 9,660,000.Looking Ahead CytoSorbents hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.Details Of The Call Date: Aug 04, 2020View more earnings on CTSOTime: 04:45 PMET Webcast URL: Action 52-week high: 11.74Companys 52-week low was at 3.49Price action over last quarter: down 9.95Company Overview CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries.The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The companys product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.See more from Benzinga Earnings Outlook for CytoSorbents 17 Healthcare Stocks Moving In Mondays Pre-Market SessionC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 